Teva in talks to settle US lawsuit alleging MS drug kickbacks
By Nate Raymond
BOSTON, June 17 (Reuters) -Teva Pharmaceutical Industries Ltd TEVA.TA said it is in active talks to settle a U.S. Department of Justice lawsuit alleging it used charities that help cover Medicare patients' out-of-pocket drug costs as a means to pay kickbacks to boost sales of its multiple sclerosis drug Copaxone.
Teva made the disclosure on Sunday in a filing asking the Boston-based 1st U.S. Circuit Court of Appeals to put on hold its appeal set to be heard next month of a key ruling over what the government must prove to establish it violated the False Claims Act.
That law makes it illegal to defraud governmental programs and allows the government and whistleblowers to pursue civil cases seeking to recover taxpayer money paid out based on false claims submitted for payment.
"The parties are actively engaged in settlement negotiations and Teva is optimistic that the parties can reach a resolution, but additional time is needed to do so," Teva's lawyers wrote.
The case is one of two left pending from an industry-wide probe of drugmakers' financial support of patient assistance charities that has resulted in more than $1 billion in settlements with 12 drugmakers, four charities and one pharmacy.
Teva in court papers had said that it faced triple damages under the False Claims Act of as much as $10 billion in the Justice Department's lawsuit, which was filed in 2020. It has denied wrongdoing.
Israel-based Teva and the U.S. Attorney's Office in Massachusetts, which has been handling the case, declined to comment on Monday.
Drug companies are prohibited from subsidizing co-payments for patients enrolled in Medicare, the government healthcare program for those aged 65 and older. Companies may donate to non-profits providing co-pay assistance as long as they are independent.
But the government has alleged that various pharmaceutical companies used such charities as a means to improperly pay the co-pay obligations of Medicare patients using their drugs, in violation of the Anti-Kickback Statute.
The lawsuit alleged Teva paid two such charitable foundations, the Chronic Disease Fund and The Assistance Fund, more than $350 million from 2006 to 2017 to cover co-payments for Copaxone patients, turning the charities into vehicles to pay kickbacks to patients to use the drug.
During that time, Teva quintupled the drug's price to about $85,000 per year from approximately $17,000. The drug at that time was Teva's best seller, generating $3.8 billion in revenues in 2017 alone.
The industry-wide investigation was launched during heightened attention to rising drug prices. Co-pays are partly meant to serve as a check on healthcare expenses by exposing patients to some of a medicine's true cost.
The 1st Circuit had scheduled arguments on July 22 in both the case against Teva and a similar lawsuit filed in 2020 against Regeneron Pharmaceuticals Inc on the issue of what government must prove at trial.
In Teva's case, the company was appealing U.S. District Judge Nathaniel Gorton's decision last year holding the government did not have to prove that specific Medicare payments would not have been made if not for illegal kickbacks.
In Regeneron's case, Chief U.S. District Judge F. Dennis Saylor reached the opposite conclusion. Both judges allowed Teva and Regeneron to pursue appeals now instead of going to trial first given the importance of the question to the litigation.
The case is United States v. Teva Pharmaceuticals USA Inc, 1st U.S. Circuit Court of Appeals, No. 23-1958.
For the government: Daniel Winik of the U.S. Department of Justice
For Teva: Alexandra Shapiro of Shapiro Arato Branch and William Peterson of Morgan, Lewis & Bockius
Read more:
Trial against Teva over kickback claims put on hold amid appeal
U.S. sues Teva over alleged kickbacks for multiple sclerosis drug
Reporting by Nate Raymond in Boston
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
